

## **Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics**

De Smet D. (MD)<sup>1</sup>, De Smet K. (MD)<sup>2</sup>, Herroelen P. (MSc.)<sup>1</sup>, Gryspeerdt S. (MD)<sup>2</sup> and Martens G.A. (MD, PhD)<sup>1,3</sup>

<sup>1</sup> AZ Delta Medical Laboratories and <sup>2</sup> Department of Radiology, AZ Delta General Hospital, Roeselare, Belgium <sup>3</sup> VUB Metabolomics platform, Brussels Free University

Corresponding author: geert.martens@azdelta.be, AZ Delta Medical Laboratories, AZ Delta General Hospital, Deltalaan 1, 8800 Roeselare. Tel:+32 51 23 71 96

Word count: 1175

## Key points

- **Question:** does vitamin D deficiency predispose to severity of SARS-CoV-2 infection?
- **Findings:** in this observational study on 186 consecutive patients hospitalized with PCR-confirmed SARS-CoV-2 infection, we find that patients with severe COVID-19 show lower median serum 25(OH)D and a higher percentage of vitamin D deficiency at intake than a season/age-matched reference population. The correlation between vitamin D deficiency and the need for hospitalization due to COVID-19 was only seen in male patients. In males but not females, the percentage of vitamin D deficient patients also increased with more advanced COVID-19 disease stage as measured by CT.
- **Meaning:** our data indicate a strong statistical correlation between the degree of vitamin D deficiency and severity of COVID-19 lung disease. With more than 1 billion people worldwide affected by vitamin D deficiency, vitamin D supplementation might be a lifesaving, inexpensive, accessible and safe component of primary prevention during the SARS-CoV-2 pandemic and beyond

## Structured abstract

**Importance:** Vitamin D deficiency increases the incidence of respiratory virus infections. More than 1 billion people worldwide are vitamin D deficient. If vitamin D deficiency is associated to incidence or severity of SARS-CoV-2 infection, a global call could be made for vitamin D supplementation to mitigate the pandemic.

**Objective:** to determine if lower serum 25-hydroxyvitamin D (25(OH)D) levels are correlated to the risk for COVID-19 and its severity as measured by CT

**Design:** single-center observational study

**Setting:** AZ Delta general hospital

**Participants:** 186 consecutive patients with PCR-confirmed SARS-CoV-2 infection hospitalized for COVID-19 from March 1, 2020 to April 7, 2020

**Main outcome and measures:** comparative analysis of 25(OH)D levels in patients hospitalized for COVID-19 at various radiological stages and a season/age/sex-matched diseased control population

**Results:** we report on 186 SARS-CoV-2 infected patients requiring hospitalization for severe COVID-19: 109 males (median age 68 years, IQR 53-79 years) and 77 females (median age 71 years, IQR 65-74 years). At admission patients were screened by CT to determine temporal changes of COVID-19 lung disease and classified as stage 1 (ground glass opacities), 2 (crazy paving pattern) and 3 (consolidation). At intake, 25(OH)D levels were measured and compared to a season-matched population of 2717 diseased controls, consisting of 999 males (median age 69 years, IQR 53-81 years) and 1718 females (median age 68 years, IQR 43-83 years). Male and female COVID-19 patients combined showed lower median 25(OH)D than controls (18.6 ng/mL, IQR 12.6-25.3, versus 21.5 ng/mL, IQR 13.9-30.8;  $P=0.0016$ ) and a higher fraction of vitamin D deficiency (58.6% versus 45.2%,  $P=0.0005$ ). A strong sexual dimorphism was found: female patients had comparable vitamin D status as control females. Male COVID-19 patients, however, showed markedly higher percentage of vitamin D deficiency than controls (67.0% versus 49.2%,  $P=0.0006$ ) and this effect was more pronounced with advanced radiological stage ranging from 55.2% in stage 1 to 74% in stage 3.

**Conclusions and relevance:** vitamin D deficiency is a possible risk factor for severe SARS-CoV-2 infection in males. Vitamin D supplementation might be an inexpensive, accessible and safe mitigation for the SARS-CoV-2 pandemic.

## **Introduction**

In severe SARS-CoV-2 infections, sustained and excessive activity of pro-inflammatory immune cells and cytokines is thought to contribute to alveolar and endothelial damage, triggering a vicious cycle that evolves towards severe COVID-19 with diffuse alveolar damage<sup>1,2</sup>. Beside its role in calcium metabolism, 1,25-dihydroxyvitamin D (25(OH)D) is a pleiotropic regulator of the immune system<sup>3,4</sup>. It stimulates the expression of cathelicidins and beta-defensin in respiratory epithelia as barrier to pathogen invasion<sup>5,6</sup>. Vitamin D generally acts as a pro-survival hormone by enhancing pathogen clearance and as pro-tolerogenic cytokine dampening excessive inflammation by inhibiting neutrophils and switching Th1 CD4 T cells and M1-polarized macrophages towards a type II immunity. Vitamin D deficiency increases the severity of respiratory virus infections<sup>7,8</sup> and contributes to variations in their incidence across seasons, age groups, socioeconomic status and geographies. With up to a third of the world population affected by vitamin D deficiency<sup>9</sup>, we studied if 25-dihydroxyvitamin D (25(OH)D) levels influence the risk for COVID-19 and are correlated to its radiological stage in a cohort of 186 patients admitted to a large Belgian community hospital.

## **Methods**

*Patients* This is a retrospective observational study on 186 consecutive patients hospitalized for COVID-19 pneumonia from March 1, 2020 to April 7 at AZ Delta General Hospital in Roeselare, Belgium. The study was approved by the local ethical committee (AZ Delta Institutional Review Board, IRB number pending) with a waiver of informed consent from study participants considering the study is based on secondary analysis of existing data and poses no risks to the subjects.

*Procedures* On admission, all patients received a thorax CT (Detailed CT scanning protocol in Supplementary Information) to determine the disease stage by consensus evaluation of the predominant radiological presentation: ground-glass opacities (early stage, 0-4 days, “stage 1”), crazy paving pattern (progressive stage, 5-8 days, “stage 2”), (3) consolidation (peak stage, 10-13 days, “stage 3”)<sup>10</sup>. SARS-CoV-2 infection was confirmed in all patients by PCR for E/N/RdRP genes (Allplex™ 2019-nCoV assay, Seegene, Korea) on nasopharyngeal swab. 25(OH)D was measured on

admission by Elecsys® vitamin D total II traced to the official reference ID-LC-MS/MS (Roche, Switzerland) and referenced to levels in a diseased control population (1718 females, 999 males, aged >18 years Table 1) measured in the same laboratory during the same seasonal period from February 15, 2019 to April 15, 2019.

*Statistical analysis* Data (not normally distributed) are expressed as medians (IQR) and Mann-Whitney test was used to test statistical differences between groups. Proportions for categorical variables were compared using chi-squared test. Statistical analyses were performed using MedCalc (version 12.2.1, Belgium) and considered significant if P value was less than .05 (Exact P values listed in Supplementary Information Table S1).

## Results

*Demographics and COVID-19 disease staging.* A total of 186 SARS-CoV-2 infected patients were admitted for COVID-19 pneumonia: 109 males (median age 68 years, IQR 53-79 years) and 77 females (median age 71 years, IQR 65-74 years). On admission, patients were screened by CT to determine temporal changes of COVID-19 lung disease and classified based on the predominant radiological lesion (Fig.1D-F) as early stage 1 (ground-glass opacities), progressive stage 2 (crazy paving pattern) or peak stage 3 (consolidation). These stages are considered as proxy for the immunological phase of COVID-19 with an early phase of active viral replication in lower airways (stage 1), progressive recruitment of pro-inflammatory cells to the lung interstitial space (stage 2), ending in diffuse alveolar damage and fibrosis (stage 3). 24.7%, 29.6% and 45.7% of patients presented in stage 1, 2 and 3, respectively with similar distribution in males and females (Table 1).

*Vitamin D status in controls and COVID-19* COVID-19 patients had lower median 25(OH)D on admission (18.6 ng/mL, IQR 12.6-25.3) than a diseased control population of 2717 subjects with similar age distribution and sampled during the same season (21.5 ng/mL, IQR 13.9-20.8, P=0.0016) and a markedly higher percentage of vitamin D deficiency ((25(OH)D<20ng/mL): 58.6% versus 45.2% (P=0.0005) (Table 1). Considering the male preponderance in COVID-19 patients (59%) but underrepresentation in controls (37%), we then stratified 25(OH)D for sex (Fig.1A-C and Table 1).

Remarkably, we observed a strong sexual dimorphism. Female COVID-19 patients were not more vitamin D deficient than female controls (46.8% versus 42.8%,  $P=0.5646$ , Fig.1B). Control males showed higher vitamin D deficiency rates than control females (49.2% versus 42.8%,  $P<0.0001$  Fig.1A). In male COVID-19 patients, vitamin D deficiency was even more profound (Fig.1C), with lower median 25(OH)D (17.6 ng/mL, IQR 12.7-24.0 versus 20.3 ng/mL, IQR 13.7-28.3,  $P=0.0234$ ) and a markedly higher deficiency rate (67.0% versus 49.2%,  $P=0.0006$ ) than male controls.

*Correlation vitamin D status and disease stage* Analysis of 25(OH)D across radiological disease stages (Fig.1G-H, Table 1) strengthened the correlation: male COVID-19 patients showed significantly lower median 25(OH)D with more advanced stage resulting in progressively increasing vitamin D deficiency rates from 55.2% in stage 1, 66.7% in stage 2 and 74.0% in stage 3 ( $P=0.0010$ ). No such stage-dependent variations were seen in female COVID-19 patients.

## **Discussion**

This retrospective observational study is to our knowledge the first to show a correlation between vitamin D deficiency, the risk to be hospitalized for severe COVID-19 pneumonia and its radiological disease stage. It reveals a remarkable sexual dimorphism, with statistical correlations in male but not female COVID-19 patients. Prospective and interventional trials are needed to define if vitamin D deficiency is cause or consequence of severe COVID-19.

Sustained inflammation could induce consumption of circulating 25(OH)D, attributed to extrarenal CYP27B1 activity and VDR expressed by the expanded repertoire of immune cells. In a USA population survey, subjects with  $CRP>5$  mg/L showed 1.6 ng/L lower median 25(OH)D<sup>11</sup>. However, the stable 25(OH)D levels in female COVID-19 patients across stages argue against such effect.

The pathophysiology of severe SARS-CoV-2 infection shows similarities to that of SARS-CoV<sup>12</sup>: in individuals with delayed type I/III interferon response and delayed viral clearance, progressive recruitment of neutrophils and pro-inflammatory Th1/M1-polarized immune cells contribute to endothelial and alveolar cell death and in some patients trigger a cytokine storm<sup>1</sup> that enhances diffuse alveolar damage. Severe COVID-19 can thus be conceptualized as an unbalance between pro-inflammatory type I immune response required for viral clearance and tolerogenic type II response

required for repair <sup>1,2,12</sup>. Vitamin D modulates the immunological response to respiratory viruses at various phases: early on, it limits viral entry and replication by boosting cathelicidins/defensins expression in respiratory epithelia <sup>5</sup>, later on it exerts a tolerogenic effect by directly mediating IL-4/IL-13-dependent polarization towards M2-macrophages and Th2 CD4 T cells <sup>6</sup>. The mammalian immune system shows conserved estrogen/androgen-dependent sexual dimorphism <sup>13</sup>. SARS-CoV-infected female mice show lower viral replication, lower recruitment of inflammatory monocytes and neutrophils to the lungs and less alveolar and endothelial cell death <sup>14</sup>. If vitamin D deficiency favors a pro-inflammatory balance, the higher rates of vitamin D deficiency in male humans might thus act in concert with estrogen/androgen-dependent immune differences and contribute to higher incidence and severity in male COVID-19 patients.

Meta-analysis confirmed that vitamin D supplementation reduces the incidence and severity of acute respiratory infections <sup>15</sup>.

Though larger epidemiological surveys are needed, variations in vitamin D deficiencies across geographies, skin pigment (African/Latino), body mass (obese), socioeconomic status (poor) and lifestyle (institutionalized people) appear to coincide with the incidence and/or death rates of SARS-CoV-2 infections, suggesting a possible convergence of two pandemics and a global call for vitamin D supplementation as inexpensive, safe and readily available mitigation.

### **Conflicts of interest**

The authors declare no conflict of interest



## References

1. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020.
2. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-1034.
3. Chirumbolo S, Bjorklund G, Sboarina A, Vella A. The Role of Vitamin D in the Immune System as a Pro-survival Molecule. *Clin Ther*. 2017;39(5):894-916.
4. Cantorna MT, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. *Mol Aspects Med*. 2008;29(6):369-375.
5. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science*. 2006;311(5768):1770-1773.
6. Cantorna MT. Vitamin D and Lung Infection. *Infect Immun*. 2016;84(11):3094-3096.
7. Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. *Rev Med Virol*. 2017;27(1).
8. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. *Nutrients*. 2015;7(6):4240-4270.
9. Hilger J, Friedel A, Herr R, et al. A systematic review of vitamin D status in populations worldwide. *Br J Nutr*. 2014;111(1):23-45.
10. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020:200463.
11. Haynes BM, Pfeiffer CM, Sternberg MR, Schleicher RL. Selected physiologic variables are weakly to moderately associated with 29 biomarkers of diet and nutrition, NHANES 2003-2006. *J Nutr*. 2013;143(6):1001S-1010S.
12. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol*. 2017;39(5):529-539.
13. Trigunaitė A, Dimo J, Jorgensen TN. Suppressive effects of androgens on the immune system. *Cell Immunol*. 2015;294(2):87-94.
14. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol*. 2017;198(10):4046-4053.
15. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583.




## Figure legends

**Fig.1: 25(OH)D levels in male and female COVID-19 patients and controls and stratified by radiological disease stage** Panels A-C: Box-and-Whisker plots showing median (red line) serum 25(OH) levels and interquartile ranges (green box) in (A) season- and age-matched female (n=1718) versus male (n=999) diseased controls; (B) female COVID-19 patients on admission (n=77) versus female controls; (C) male COVID-19 patients on admission (n=109) versus male controls. Panels D-F: representative images of radiological stages of COVID-19 lung disease with predominantly (D) ground-glass opacities in early stage; (E) crazy paving patterns in progressive stage 2; and (F) consolidation in peak stage 3. Panel G-H: box-and-whisker plots of 25(OH)D in (G) female COVID-19 patients and (H) male COVID-19 patients grouped according to radiological stage. Background color in box plots indicates normal vitamin D status (green, 25(OH)D > 30 ng/mL), vitamin D insufficiency (pale red, 25(OH)D < 20 ng/mL), vitamin D deficiency (darker red, 25(OH)D < 12 ng/mL) and a gray zone (20 ng/mL ≤ 25(OH)D ≤ 30 ng/mL). P values indicate statistical differences between groups calculated by Mann-Whitney test.

## Table legends

**Table 1. Demographic characteristics of controls and COVID-19 patients and 25(OH) levels stratified by sex and radiological stage.** † Indicates differences with diseased controls for which P values less than .05 were considered statistically significant. ‡ Indicates differences with CT Stage 1 COVID-19 patients for which P values less than .05 were considered statistically significant. Data (not normally distributed) are expressed as medians (25th–75th percentiles), and the Mann-Whitney test was used to test statistical difference between groups. Proportions for categorical variables were compared using chi-squared test. All statistical analysis were performed using MedCalc and considered significant if the P value was less than .05. Exact P values listed in Supplementary information.







**Table 1. Demographic characteristics of diseased controls and COVID-19 patients and 25(OH) levels stratified by sex and radiological COVID-19 disease stage**

Patient group	Characteristic	Diseased Controls	COVID-19 (all)	COVID-19 (CT Stage 1)	COVID-19 (CT Stage 2)	COVID-19 (CT Stage 3)
All patients	n	2717	186	46	55	85
	Age, median (IQR), y	68 (49-82)	69 (52-80)	74 (53-82)	71 (60-78)	63 (50-80)
	Sex					
	Female, n (%)	1718 (63,2)	77 (41,4) †	17 (37,0) †	25 (45,5) †	35 (41,2) †
	Male, n (%)	999 (36,8)	109 (58,6) †	29 (63,0) †	30 (54,5) †	50 (58,8) †
	25-OH-Vitamin D					
	Median (IQR), ng/mL	21,5 (13,9-20,8)	18,6 (12,6-25,3) †	19,7 (16,2-30,8)	17,6 (12,0-26,0) †	16,9 (12,6-23,8) † ‡
≥ 20 ng/mL, n (%)	1490 (54,8)	77 (41,4) †	22 (47,8)	23 (41,8)	32 (37,6) †	
< 20 ng/mL, n (%)	1227 (45,2)	109 (58,6) †	24 (52,2)	32 (58,2)	53 (62,4) †	
Female patients	n	1718	77	17	25	35
	Age, median (IQR), y	68 (46-83)	71 (65-74)	68 (46-83)	72 (64-76)	66 (49-82)
	25-OH-Vitamin D					
	Median (IQR), ng/mL	22,4 (14,2-32,0)	20,7 (12,4-29,8)	20,7 (10,4-33,0)	20,3 (11,7-27,7)	21,2 (15,1-29,6)
	≥ 20 ng/mL, n (%)	983 (57,2)	41 (53,2)	9 (52,9)	13 (52,0)	19 (54,3)
< 20 ng/mL, n (%)	735 (42,8)	36 (46,8)	8 (47,1)	12 (48,0)	16 (45,7)	
Male patients	n	999	109	29	30	50
	Age, median (IQR), y	69 (53-81)	68 (53-79)	74 (58-81)	71 (59-78)	59 (52-77)
	25-OH-Vitamin D					
	Median (IQR), ng/mL	20,3 (13,7-28,4)	17,6 (12,7-24,0) †	19,4 (18,2-29,8)	16,5 (12,1-24,0) ‡	16,0 (12,0-22,1) † ‡
	≥ 20 ng/mL, n (%)	507 (50,8)	36 (33,0) †	13 (44,8)	10 (33,3)	13 (26,0) †
< 20 ng/mL, n (%)	492 (49,2)	73 (67,0) †	16 (55,2)	20 (66,7)	37 (74,0) †	

† Indicates differences with diseased controls for which P values less than .05 were considered statistically significant.

‡ Indicates differences with CT Stage 1 COVID-19 patients for which P values less than .05 were considered statistically significant.